Life Sciences Group Of The Year: Paul Hastings

Law360, New York (January 29, 2018, 3:27 PM EST) -- Paul Hastings LLP convinced the U.S. Patent Trial and Appeal Board to invalidate a major patent covering AbbVie's $16 billion biologic Humira and uphold four patents covering an Acorda Therapeutics Inc. multiple sclerosis drug, landing the firm a spot among Law360's 2017 Life Sciences Groups of the Year.

The firm’s patent practice, which life sciences Chair Bruce Wexler said has a 24-0 record at the PTAB, is complemented by a team of life sciences attorneys focused on privacy, cybersecurity, compliance, corporate work and mergers and acquisitions....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.